Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Black Swift Group LLC

Black Swift Group LLC reduced its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 45.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,000 shares of the medical equipment provider's stock after selling 5,000 shares during the period. Black Swift Group LLC's holdings in Lantheus were worth $537,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. State of New Jersey Common Pension Fund D boosted its stake in shares of Lantheus by 0.4% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider's stock worth $2,364,000 after purchasing an additional 115 shares during the last quarter. Bleakley Financial Group LLC lifted its holdings in shares of Lantheus by 6.1% during the 4th quarter. Bleakley Financial Group LLC now owns 2,237 shares of the medical equipment provider's stock worth $200,000 after acquiring an additional 129 shares during the period. UMB Bank n.a. lifted its holdings in shares of Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after acquiring an additional 134 shares during the period. Arizona State Retirement System lifted its holdings in shares of Lantheus by 0.9% during the 4th quarter. Arizona State Retirement System now owns 20,137 shares of the medical equipment provider's stock worth $1,801,000 after acquiring an additional 178 shares during the period. Finally, Wilmington Savings Fund Society FSB purchased a new position in shares of Lantheus during the 3rd quarter worth about $25,000. 99.06% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. StockNews.com lowered shares of Lantheus from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. The Goldman Sachs Group started coverage on shares of Lantheus in a report on Wednesday, December 18th. They set a "buy" rating and a $143.00 price objective on the stock. JMP Securities restated a "market outperform" rating and issued a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. Finally, Truist Financial raised their price target on shares of Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $132.86.

Lantheus Stock Up 6.1 %

Shares of LNTH traded up $6.11 during mid-day trading on Friday, reaching $106.34. 1,369,851 shares of the stock traded hands, compared to its average volume of 921,738. The firm has a market cap of $7.28 billion, a price-to-earnings ratio of 17.69 and a beta of 0.38. The stock has a fifty day simple moving average of $90.71 and a 200 day simple moving average of $96.85. Lantheus Holdings, Inc. has a 12-month low of $56.44 and a 12-month high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The firm had revenue of $391.11 million for the quarter, compared to analysts' expectations of $376.61 million. On average, equities research analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Insider Transactions at Lantheus

In other news, Director Mary Anne Heino sold 53,107 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now owns 440,399 shares of the company's stock, valued at approximately $41,551,645.65. This trade represents a 10.76 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director James H. Thrall sold 1,000 shares of the firm's stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the sale, the director now directly owns 33,207 shares of the company's stock, valued at $3,146,695.32. The trade was a 2.92 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.50% of the company's stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.